Page 1 | Search Results | Cancer Research | American Association for Cancer Research

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Abstract CT537: A phase 2, multicenter, randomized, double-blind trial of maintenance therapy with FLT3 inhibitor gilteritinib (ASP2215) in patients with FLT3/ITD AML (GOSSAMER study)

Mark D. Minden, Jacob M. Rowe, Emmanuel Gyan, Kohmei Kubo, Nahla Hasabou, David Delgado, Wensheng He, Stanley C. Gill, Jason E. Hill, Ramon Tiu

Cancer Res (2022) 82 (12_Supplement): CT537.

https://doi.org/10.1158/1538-7445.AM2022-CT537

Published: 15 June 2022

View article titled, Abstract CT537: A phase 2, multicenter, randomized, double-blind trial of maintenance therapy with FLT3 inhibitor gilteritinib (ASP2215) in patients with FLT3/ITD AML (GOSSAMER study)

Journal Articles

Inhibition of p53 Response in Tumor Stroma Improves Efficacy of Anticancer Treatment by Increasing Antiangiogenic Effects of Chemotherapy and Radiotherapy in Mice

Lyudmila G. Burdelya, Elena A. Komarova, Jason E. Hill, Timothy Browder, Natalia D. Tararova, Lori Mavrakis, Paul E. DiCorleto, Judah Folkman, Andrei V. Gudkov

Cancer Res (2006) 66 (19): 9356–9361.

https://doi.org/10.1158/0008-5472.CAN-06-1223

Published: 03 October 2006

View article titled, Inhibition of p53 Response in Tumor Stroma Improves Efficacy of Anticancer Treatment by Increasing Antiangiogenic Effects of Chemotherapy and Radiotherapy in Mice

Journal Articles

Targeted si-RNA mediated down-regulation of topoisomerase II α or β isozymes defines selectivity to inhibitors of the enzyme

Kenichi Chikamori, Jason E. Hill, Adrian G. Grozav, Dale R. Grabowski, Susan A. J. Vaziri, Andrei V. Gudkov, Ronald M. Bukowski, Ram Ganapathi, Mahrukh K. Ganapathi

Cancer Res (2005) 65 (9_Supplement): 563.

Published: 01 May 2005

View article titled, Targeted si-RNA mediated down-regulation of topoisomerase II α or β isozymes defines selectivity to inhibitors of the enzyme

Journal Articles

Mechanism of action associated with response to erbB receptor targeted therapy

Sarah S. Bacus, Jason E. Hill, Neil L. Spector

Cancer Res (2005) 65 (9_Supplement): 637.

Published: 01 May 2005

View article titled, Mechanism of action associated with response to erbB receptor targeted therapy

Journal Articles

p53 Pathway in Renal Cell Carcinoma Is Repressed by a Dominant Mechanism

Katerina V. Gurova, Jason E. Hill, Olga V. Razorenova, Peter M. Chumakov, Andrei V. Gudkov

Cancer Res (2004) 64 (6): 1951–1958.

https://doi.org/10.1158/0008-5472.CAN-03-1541

Published: 16 March 2004

View article titled, p53 Pathway in Renal Cell Carcinoma Is Repressed by a Dominant Mechanism

NARROW

Abstract CT537: A phase 2, multicenter, randomized, double-blind trial of maintenance therapy with FLT3 inhibitor gilteritinib (ASP2215) in patients with FLT3/ITD AML (GOSSAMER study)

Inhibition of p53 Response in Tumor Stroma Improves Efficacy of Anticancer Treatment by Increasing Antiangiogenic Effects of Chemotherapy and Radiotherapy in Mice

Targeted si-RNA mediated down-regulation of topoisomerase II α or β isozymes defines selectivity to inhibitors of the enzyme

Mechanism of action associated with response to erbB receptor targeted therapy

p53 Pathway in Renal Cell Carcinoma Is Repressed by a Dominant Mechanism

Email alerts

AACR Journals

Abstract CT537: A phase 2, multicenter, randomized, double-blind trial of maintenance therapy with FLT3 inhibitor gilteritinib (ASP2215) in patients with FLT3/ITD AML (GOSSAMER study)

Inhibition of p53 Response in Tumor Stroma Improves Efficacy of Anticancer Treatment by Increasing Antiangiogenic Effects of Chemotherapy and Radiotherapy in Mice

Targeted si-RNA mediated down-regulation of topoisomerase II α or β isozymes defines selectivity to inhibitors of the enzyme

Mechanism of action associated with response to erbB receptor targeted therapy

p53 Pathway in Renal Cell Carcinoma Is Repressed by a Dominant Mechanism

Email alerts

AACR Journals

This Feature Is Available To Subscribers Only